Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis

Summary

This trial was designed to evaluate the efficacy and safety of SHR-1819 injection in patients with atopic dermatitis.

Timeline

Start

2022-10-08

Primary completion

2023-09-15

Completion

2023-11-23

Outcome

Met primary endpoint

paper all nominal p < 0.01 PMID 42210243 ↗

Publications

• Gu C, Yin H, Yang B, Ji S, Bian K, Man X, Lu J, Sui D, Zhou Y, Cheng F, Xu A, Li X, Jiang M, Diao Q, Ji C, Shi T, Ding Y, Ren H, Li Y, Liu H, Meng Z, Feng P, Zhang S, Bai X, Li P, Dong Y, Liu S, Zhang C, Xu J. Anti-IL-4Ralpha antibody SHR-1819 for moderate-to-severe atopic dermatitis: a randomized phase 2 study. BMC Med. 2026 May 28. doi: 10.1186/s12916-026-04952-3. Online ahead of print.

Drugs

Indications